Univercell-Biosolutions S.A.S   Report issue

For profit Phase 3
Founded: Toulouse France (2010)

Organization Overview

First Clinical Trial
2019
NCT03737461
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Univercell-Biosolutions S.A.S

Active Ingredients

Drugs in Phase 3 Trials (1)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Intervertebral Disc Degeneration (Phase 3)

Low Back Pain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1